Tubulis Entered into a License Agreement with BMS to Develop ADCs Therapies for the Treatment of Cancer
Shots:
- Tubulis will receive $22.75M up front, ~$1B in development, regulatory & commercial milestones along with royalty on net product sales
- BMS will obtain an exclusive right to access Tubulis’ Tubutecan payloads in combination with the P5 conjugation platform to develop selected no. of highly differentiated ADCs for solid tumors & will lead the development, manufacturing & commercialization of the resulting ADC candidates. Once BMS selects Ab targets, Tubulis will provide its linker payload to generate a uniquely matched ADC for each Ab
- The collaboration combines BMS’ deep oncology & clinical development expertise & Tubulis’ differentiated and unique approach to ADC design to delivers ADC therapies
Ref: BusinessWire | Image: Tubulis
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
